A Mini Review on New Drugs Approved in 2021

Agnihotri, Akash; Ramasubbu, Saravana kumar

doi:10.47363/jjcmr/2022(2)131

Jap J Clin & Med Res

2022

DOI: 10.47363/jjcmr/2022(2)131

|View full text |Cite

A Mini Review on New Drugs Approved in 2021

Akash Agnihotri¹,

Saravana kumar Ramasubbu²

Abstract: In 2021, the US Food and Drug Administration approved 50 novel drugs. Twenty three of the 50 (46%) drugs were categorized as orphan drug, and 9 of the 50 (18%) were approved under accelerated approval. This review includes a summary of the novel drugs approved by the US Food and Drug Administration in 2021

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2023

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

A review of new drugs approved by the food and drug administration in 2022

Swaminathan,

Vijayakumar,

Nikhithaa

2023

Journal of Family Medicine and Primary Care

View full text Add to dashboard Cite

Introduction: The drugs approved by the Food and Drug Administration (FDA) in 2022, for the first time for any indication or under any brand, were studied under the contexts of indications, mechanism of action, and side effects. Primary care practitioners with considering patients as a composite whole will benefit by acquainting themselves with these drugs and their indications and adverse effects. Observations: The drugs were approved in all, 11 for the management of neoplasia, and 5 each for hematological, neurological, and dermatological conditions. 11 of the approved drugs are monoclonal antibodies and six are small molecule inhibitors. Conclusion: Although the FDA’s expedited approval program allows rapid market availability of drugs for difficult to treat conditions, a quarter of the globe does not have access to essential medicines, primarily due to cost. In light of this, approval agencies must reorient approval processes to improve accessibility.

show abstract

A review of new drugs approved by the food and drug administration in 2022

Swaminathan,

Vijayakumar,

Nikhithaa

2023

Journal of Family Medicine and Primary Care

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A Mini Review on New Drugs Approved in 2021

Cited by 1 publication

References 0 publications

A review of new drugs approved by the food and drug administration in 2022

A review of new drugs approved by the food and drug administration in 2022

Contact Info

Product

Resources

About